Tocilizumab in severe COVID-19 – A randomized, double-blind, placebo-controlled trial

BACKGROUND: The therapeutic effectiveness of interleukin-6 receptor inhibitor in critically ill hospitalized patients with coronavirus disease 2019 (COVID-19) is uncertain. METHODS: To evaluate the efficacy and safety of the outcome as recovery or death of tocilizumab for severe acute respiratory sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Malik, Muhammad Irfan, Zafar, Sardar Al Fareed, Qayyum, Fabiha, Malik, Muna, Asghar, Muhammad Sohaib, Tahir, Muhammad Junaid, Arshad, Ammarah, Khalil, Fatima, Naz, Hafiza Shafia, Aslam, Mudassar, Saleem, Jodat, Aziz, Abdul, Azhar, Mustafa Usman, Naqash, Muhammad, Yousaf, Zohaib
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of Tsinghua University Press. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161690/
https://www.ncbi.nlm.nih.gov/pubmed/38013720
http://dx.doi.org/10.1016/j.imj.2022.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161690/
https://www.ncbi.nlm.nih.gov/pubmed/38013720
http://dx.doi.org/10.1016/j.imj.2022.05.001

Ejemplares similares